Fibronectin type III domain-containing protein 3B mRNA (FNDC3B mRNA)

Fibronectin type III domain-containing protein 3B (FNDC3B) mRNA, also known as FAD104, encodes an endoplasmic reticulum-anchored transmembrane protein that plays a critical role in cell adhesion, migration, and differentiation (UniProt, 1.4.2). It is a well-characterized positive regulator of adipogenesis and a negative regulator of osteoblast differentiation (NIH, 1.3.1). In the context of oncology, FNDC3B acts as a potent oncogene; its gene locus at 3q26 is frequently amplified in various malignancies, including hepatocellular carcinoma, glioblastoma, and pancreatic cancer (Oncotarget, 1.3.4). Overexpression of FNDC3B mRNA promotes the epithelial-mesenchymal transition (EMT) and metastasis by activating pathways such as PI3K/Akt, TGF-beta, and Wnt/beta-catenin (NIH, 1.3.5). As a therapeutic target, FNDC3B mRNA is primarily approached through RNA-interference (RNAi) and antisense technologies to silence its expression and inhibit tumor progression (NIH, 1.3.1). Preclinical studies have demonstrated that knocking down FNDC3B mRNA significantly reduces cell invasion and enhances the apoptotic effects of conventional chemotherapies in models of glioblastoma and hepatocellular carcinoma (NIH, 1.2.2). While no small-molecule inhibitors are currently approved, the mRNA remains a high-priority target for the development of precision nucleic acid therapeutics. However, challenges include ensuring specific delivery to tumor tissues and avoiding potential side effects related to its physiological roles in metabolic homeostasis and neonatal lung development (NIH, 1.3.1, 1.3.2).

Other names

FAD104Factor for adipocyte differentiation 104NS5ABP37YVTM2421PRO4979HCV NS5A-binding protein 37

RNA interference and antisense inhibition to reduce the expression of the FNDC3B protein, thereby inhibiting oncogenic signaling and metastasis.